Core Insights - Jazz Pharmaceuticals presented new real-world evidence and Phase 4 data at World Sleep 2025 and the Psych Congress, highlighting the effectiveness of Xywav in treating narcolepsy and idiopathic hypersomnia [1][2][6] Group 1: Clinical Trial Results - The Phase 4 DUET trial demonstrated that low-sodium Xywav significantly improves daytime and nighttime symptoms in adults with narcolepsy or idiopathic hypersomnia [1][6] - Participants in the DUET trial experienced fewer awakenings and improved sleep measures, indicating enhanced sleep quality [6] - The analysis of the DUET data showed reduced sleep inertia and improved alertness among participants receiving optimized Xywav treatment [6] Group 2: Real-World Evidence - Real-world analyses indicated that individuals with narcolepsy or idiopathic hypersomnia face elevated risks of cardiovascular and cardiometabolic conditions, emphasizing the need for sodium intake reduction [6][8] - The data presented at the congresses reinforce the importance of understanding treatment impacts on both daytime and nighttime symptoms for patients [2][6] Group 3: Xywav Overview - Xywav is the only low-sodium oxybate approved by the FDA for treating cataplexy and excessive daytime sleepiness in patients aged 7 and older with narcolepsy [11] - It is also the first FDA-approved treatment for idiopathic hypersomnia in adults, addressing multiple symptoms including excessive daytime sleepiness and sleep inertia [12] - Xywav has a significantly lower sodium content compared to other oxybate therapies, providing a safer option for patients sensitive to sodium intake [11][12] Group 4: Company Positioning - Jazz Pharmaceuticals aims to leverage both Phase 4 clinical trials and real-world evidence to enhance understanding of sleep disorders and improve treatment outcomes [2][40] - The company is dedicated to developing innovative therapies for serious diseases, with a focus on sleep disorders and oncology [40][41]